Literature DB >> 1867238

Pyomyositis in patients with the human immunodeficiency virus: an unusual form of disseminated bacterial infection.

C A Widrow1, S M Kellie, B R Saltzman, U Mathur-Wagh.   

Abstract

PURPOSE AND PATIENTS: Pyomyositis, a common disease in the tropics, is rare in the continental United States, with approximately 83 cases described in the literature in the past two decades. The occurrence of pyomyositis complicating human immunodeficiency virus (HIV) infection has been reported in 10 patients since 1986. We report six cases of this entity in patients with advanced HIV disease seen in our institution over a 20-month period. A common denominator in all of our patients was muscle injury, induced by either exercise or trauma. Unlike most previous reports of HIV-associated pyomyositis, the clinical picture in our cases was complicated by the development of abscesses in multiple muscle groups, requiring prolonged antimicrobial therapy and repeated drainage procedures for successful management. Interestingly, one patient developed concomitant rhabdomyolysis--an otherwise rare event in classical pyomyositis. Staphylococcus aureus was the predominant infecting organism in this as well as all other series. Of note, we also observed and report the first case, to our knowledge, of gram-negative pyomyositis in an HIV-infected individual. The pathogenic implications of this catalase-producing gram-negative isolate are discussed in the context of neutrophil abnormalities in HIV disease.
CONCLUSION: Like tropical pyomyositis, its HIV-associated counterpart appears to be multifactorial in origin. Its recent recognition suggests that, in addition to underlying abnormalities of host defense, factors relating to the prolonged survival of patients with late-stage disease, including myopathy, might play an important contributory role.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1867238     DOI: 10.1016/0002-9343(91)90004-h

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  9 in total

1.  Tropical pyomyositis.

Authors:  L Ansaloni
Journal:  World J Surg       Date:  1996-06       Impact factor: 3.352

Review 2.  Nontropical pyomyositis in patients with AIDS.

Authors:  S J Antony; D S Kernodle
Journal:  J Natl Med Assoc       Date:  1996-09       Impact factor: 1.798

Review 3.  Bacterial, fungal, parasitic, and viral myositis.

Authors:  Nancy F Crum-Cianflone
Journal:  Clin Microbiol Rev       Date:  2008-07       Impact factor: 26.132

Review 4.  Enterobacter cloacae pyomyositis complicating chronic granulomatous disease and review of gram-negative bacilli pyomyositis.

Authors:  M Gousseff; F Lanternier; A Ferroni; O Chandesris; N Mahlaoui; O Hermine; O Lortholary; M Lecuit
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2013-02-01       Impact factor: 3.267

5.  Tubular aggregates and partial cytochrome c oxidase deficiency in skeletal muscle of patients with AIDS treated with zidovudine.

Authors:  P Chariot; E Benbrik; A Schaeffer; R Gherardi
Journal:  Acta Neuropathol       Date:  1993       Impact factor: 17.088

6.  Nasopharyngeal carriage of Staphylococcus aureus and carriage of tetracycline-resistant strains associated with HIV-seropositivity.

Authors:  M Amir; J Paul; B Batchelor; S Kariuki; J Ojoo; P Waiyaki; C Gilks
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1995-01       Impact factor: 3.267

7.  High Prevalence of Malnutrition among the Above Thirteen with Primary Pyomyositis in Northern Uganda.

Authors:  David Lagoro Kitara; Paul Okot Bwangamoi; Henry Wabinga; Michael Odida
Journal:  Br J Med Med Res       Date:  2015

Review 8.  Secondary myopathy due to systemic diseases.

Authors:  J Finsterer; W N Löscher; J Wanschitz; S Quasthoff; W Grisold
Journal:  Acta Neurol Scand       Date:  2016-02-25       Impact factor: 3.209

Review 9.  Infective myositis.

Authors:  Gayathri Narayanappa; Bevinahalli Nanjegowda Nandeesh
Journal:  Brain Pathol       Date:  2021-05       Impact factor: 6.508

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.